We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$4.5B
Cap. Flow
% of AUM
10.34%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,819
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$424M |
| 2 |
Kenvue
KVUE
|
+$415M |
| 3 |
Cummins
CMI
|
+$374M |
| 4 |
Bunge Global
BG
|
+$310M |
| 5 |
Newell Brands
NWL
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$423M |
| 2 |
Qualcomm
QCOM
|
+$413M |
| 3 |
D.R. Horton
DHI
|
+$401M |
| 4 |
Booking.com
BKNG
|
+$397M |
| 5 |
Phillips 66
PSX
|
+$389M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 12.39% |
| 4 | Healthcare | 10.91% |
| 5 | Technology | 10.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ETNB
1351
DELISTED
89bio
ETNB
| $25K | ﹤0.01% |
+2,146
| New | +$23.8K |
|
1352
Fate Therapeutics
FATE
$272M
| $24.9K | ﹤0.01% |
+3,394
| New | +$21K |
|
1353
NETSCOUT
NTCT
$2.89B
| $24.9K | ﹤0.01% |
1,138
+261
| +30% | +$5.66K |
|
1354
Myriad Genetics
MYGN
$503M
| $24.7K | ﹤0.01% |
+1,160
| New | +$24.9K |
|
1355
Arcturus Therapeutics
ARCT
$162M
| $24.7K | ﹤0.01% |
+731
| New | +$25.9K |
|
1356
MaxLinear
MXL
$5.37B
| $24.4K | ﹤0.01% |
1,307
+964
| +281% | +$19.2K |
|
1357
Replimune Group
REPL
$492M
| $24.4K | ﹤0.01% |
+2,984
| New | +$24.5K |
|
1358
MacroGenics
MGNX
$241M
| $24.1K | ﹤0.01% |
+1,639
| New | +$24.8K |
|
|
FARO
1359
DELISTED
Faro Technologies
FARO
| $23.9K | ﹤0.01% |
1,109
| – | – |
|
|
RNAM
1360
DELISTED
Avidity Biosciences
RNAM
| $23.8K | ﹤0.01% |
+931
| New | +$14.6K |
|
1361
Xencor
XNCR
$1.46B
| $23.5K | ﹤0.01% |
+1,064
| New | +$23K |
|
1362
Axcelis
ACLS
$3.59B
| $23.3K | ﹤0.01% |
209
+65
| +45% | +$7.75K |
|
1363
Booz Allen Hamilton
BAH
$8.73B
| $23.3K | ﹤0.01% |
157
| – | – |
|
1364
4D Molecular Therapeutics
FDMT
$511M
| $23.2K | ﹤0.01% |
+729
| New | +$18.6K |
|
1365
Sana Biotechnology
SANA
$899M
| $23.1K | ﹤0.01% |
+2,309
| New | +$17.3K |
|
1366
Vir Biotechnology
VIR
$1.48B
| $22.3K | ﹤0.01% |
2,203
+2,044
| +1,286% | +$20.8K |
|
|
VISN
1367
Vistance Networks Inc
VISN
$2.62B
| $22.1K | ﹤0.01% |
16,842
+5,856
| +53% | +$11.5K |
|
1368
Cogent Biosciences
COGT
$6.82B
| $22K | ﹤0.01% |
+3,279
| New | +$20.3K |
|
|
INFN
1369
DELISTED
Infinera Corporation Common Stock
INFN
| $22K | ﹤0.01% |
3,641
+2,762
| +314% | +$13.9K |
|
1370
Zentalis Pharmaceuticals
ZNTL
$322M
| $21.8K | ﹤0.01% |
+1,386
| New | +$19.1K |
|
1371
Travere Therapeutics
TVTX
$5.18B
| $21.4K | ﹤0.01% |
+2,771
| New | +$23.4K |
|
|
SLNO
1372
DELISTED
Soleno Therapeutics
SLNO
| $21K | ﹤0.01% |
+491
| New | +$22.2K |
|
1373
ADMA Biologics
ADMA
$2.02B
| $20.9K | ﹤0.01% |
+3,174
| New | +$17.3K |
|
1374
Apogee Therapeutics
APGE
$10.1B
| $20.6K | ﹤0.01% |
+310
| New | +$13.5K |
|
|
ECC
1375
Eagle Point Credit Company
ECC
$497M
| – | – |
0
| – | – |
|
Similar funds
SAM
Pacer Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Pacer Advisors held 3,819 positions worth $43.5B, up 23% from $35.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $4.5B of net new capital in Q1 2024, opening 249 new positions and adding to 1,063 existing holdings. Its largest new stake was Hanesbrands: 32,772,533 shares worth $190M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 19% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $423M trimmed.
- Pacer Advisors's largest Q1 2024 buy was Hanesbrands: 32,772,533 shares worth $190M.
- Pacer Advisors added most to AT&T in Q1 2024, an estimated $424M increase.
- Pacer Advisors's biggest Q1 2024 reduction was AbbVie, cutting an estimated $423M.
- Pacer Advisors fully exited Tri Pointe Homes in Q1 2024, selling an estimated $139M.
- Pacer Advisors's ten largest holdings make up 12% of its $43.5B portfolio in Q1 2024.
- Pacer Advisors opened 249 new positions and closed 119 in Q1 2024.
- Pacer Advisors's portfolio value rose 23% quarter-over-quarter to $43.5B.
Based on Pacer Advisors's 13F filing for Q1 2024, filed 10 May 2024.